drug pricing

The Readout Elaine Chen

STAT Plus: Lilly doubles down on radiopharma

The Readout Meghana Keshavan

STAT Plus: The biotech news you need to read this morning

The Readout Meghana Keshavan

AstraZeneca antibody reduced Covid-19 risk in immunocompromised

The Readout Elaine Chen

STAT Plus: Blackstone wants in on red-hot immunology market

The Readout Elaine Chen

STAT Plus: Leqembi gets closer to being offered as an injection

First Opinion Robin Feldman

Cutting-edge insulin is good. But it’s the ‘trailing edge’ of older versions that can keep it affordable

The Readout Elaine Chen

Is Novavax a new meme stock?

The Readout Meghana Keshavan

STAT Plus: We now know Tome’s gene editing target

The Readout Meghana Keshavan

STAT Plus: The public wants Medicare to cover obesity drugs

The Readout Elaine Chen

STAT Plus: Yet another big financing round in immunology

The Readout Elaine Chen

STAT Plus: Pharma has over $500B in capital for deals

The Readout Elaine Chen

STAT Plus: Vertex starts gene therapy Casgevy in five patients 

First Opinion Jason Shafrin, Louis Garrison, and Melanie D. Whittington

The world is relying on the United States to get value-based drug pricing right

The Readout Meghana Keshavan

STAT Plus: Merck may have a competition for ever-scarce BCG

The Readout Meghana Keshavan

STAT Plus: ICER casts doubt on Sarepta’s DMD gene therapy

Politics John Wilkerson

STAT Plus: Senate drug shortage bill would pay hospitals bonuses for good contracting practices

The Readout Elaine Chen

STAT Plus: The biotech news you need to read this morning

The Readout Elaine Chen

STAT Plus: The latest government crackdowns on biotech you need to know

Pharmalot Ed Silverman

STAT Plus: FTC issues warnings on ‘junk’ patent listings for Ozempic and other drugs

The Readout Elaine Chen

STAT Plus: FDA wants to hear your thoughts on advisory committees 

Politics Rachel Cohrs Zhang

STAT Plus: Federal judge rules against two drugmakers challenging Medicare drug price negotiation program

Pharmalot Ed Silverman

STAT Plus: Vertex offers limited access to a cystic fibrosis drug in South Africa — and may undercut a court case

Pharmalot Ed Silverman

STAT Plus: Thanks to CVS, a biosimilar version of AbbVie’s Humira is grabbing huge market share

The Readout Damian Garde

STAT Plus: What about the company Vertex didn’t buy?

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about AstraZeneca CEO pay, alternatives to WuXi and more

The Readout Damian Garde

STAT Plus: Gas prices are hurting biotech

Pharmalot Ed Silverman

STAT Plus: Regeneron accused by Justice Department of manipulating Medicare pricing

The Readout Meghana Keshavan

STAT Plus: AskBio CSO steps down, has new project in stealth mode

The Readout Damian Garde

STAT Plus: Pfizer’s plot to win the RSV vaccine race